



Robert Jaffe/Evan Pondel  
PondelWilkinson Inc.  
(310) 279-5980

## **LANNETT COMPANY PROVIDES UPDATE ON MARKETING DIGOXIN TABLETS**

**Philadelphia, PA – April 2, 2009** – Lannett Company, Inc. (AMEX:LCI), a manufacturer of generic pharmaceuticals, said today that it is prepared to supply the U.S. market with an uninterrupted and safe supply of Digoxin Tablets, following the voluntary recall, announced yesterday, of the drug by another generic drug manufacturer.

Lannett said it has secured additional active pharmaceutical ingredient (API) for their Digoxin Tablets, 0.125 mg and 0.25 mg. According to Wolters Kluwer, total sales of Digoxin Tablets for the last three months were \$29 million.

“We want to reassure all of our customers as well as the general public that we are prepared to supply this difficult to source medication,” said Arthur Bedrosian, president and chief executive officer of Lannett.

Digoxin is indicated for the treatment of mild to moderate heart failure as well as for the control of ventricular response rate in patients with chronic atrial fibrillation.

### **About Lannett Company, Inc.:**

Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of indications. For more information, visit the company’s website at [www.lannett.com](http://www.lannett.com).

*This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Any such statements, including, but not limited to, the successful commercialization of Digoxin Tablets, the future financial performance of Lannett Company, whether expressed or implied, are subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated due to a number of factors which include, but are not limited to, the ability to successfully commercialize products upon approval, future inventory levels, future competition or pricing, future levels of operating expenses, and other risk factors discussed in the company’s Form 10-K and other documents filed with the Securities and Exchange Commission.*

###